KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash from Investing Activities (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Cash from Investing Activities data on record, last reported at $220.3 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 37.16% year-over-year to $220.3 million; the TTM value through Dec 2025 reached -$629.1 million, up 74.51%, while the annual FY2025 figure was -$629.1 million, 74.51% up from the prior year.
  • Cash from Investing Activities reached $220.3 million in Q4 2025 per REGN's latest filing, up from -$402.9 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $647.5 million in Q1 2025 and bottomed at -$2.4 billion in Q2 2023.
  • Average Cash from Investing Activities over 5 years is -$654.5 million, with a median of -$496.3 million recorded in 2023.
  • The widest YoY moves for Cash from Investing Activities: up 629.61% in 2024, down 615.78% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$1.1 billion in 2021, then crashed by 75.42% to -$1.9 billion in 2022, then surged by 96.44% to -$66.2 million in 2023, then skyrocketed by 629.61% to $350.6 million in 2024, then tumbled by 37.16% to $220.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $220.3 million in Q4 2025, -$402.9 million in Q3 2025, and -$1.1 billion in Q2 2025.